On the recordJune 7, 2021
per an agreement that was reached with my colleagues, Dr. Eric Lander, the President's nominee for the Director of the Office of Science and Technology Policy was not subject to a rollcall vote on the Senate floor, but was instead considered under a voice vote. I would like to be on the record that I am opposed to the nomination of Dr. Lander. As OSTP Director, Dr. Lander will advise the President and the administration on all the scientific, technological, and engineering aspects of Federal policy, including Federal research. Dr. Lander should receive even further scrutiny for this position after President Biden has chosen to elevate the Director of the OSTP to a Cabinet-level position. This nomination comes at a critical time as the Senate seeks to pass the Endless Frontier Act, which would increase Federal scientific research and development funding--imprudently in my opinion--by over $100 billion. As I have weighed the nomination of Dr. Lander both in the Senate Commerce Committee and in the weeks leading up to his consideration by the full Senate, Dr. Lander has failed to provide the guarantees that he supports appropriate guardrails around federally funded research, including protections for unborn life through the prohibition of experimenting with aborted fetal tissue, embryonic stem cells, or live embryos.…





